Opthea Ltd has released a press release.
Opthea Completes Final Patient Visit in Phase 2b wAMD Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Opthea
- S&P DJI Announces March 2019 Quarterly Rebalance
- Opthea Ph2b Trial Advances With 2nd Positive Safety Review
- Opthea Granted Japanese Patent Covering OPT-302
- Opthea Options Exercise Generates Proceeds of A$13.3m
- Opthea confirms final patient enrolment in Ph2b wAMD trial
Later from Opthea
- Opthea Provides Timing Update on OPT-302 Clinical Trials
- Opthea European Patent Application to be Granted
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302
- Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA
- Opthea Presentation for EURETINA Congress
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea